Bharat Biotech’s Covid-19 Nasal Vaccine Gets Centre’s Nod For Use

New Delhi: Central Drugs Standard Control Organisation (CDSCO) has approved Bharat Biotech’s Chimpanzee Adenovirus Vectored recombinant nasal vaccine against Covid-19.

The vaccine has been approved by CDSCO for primary immunization against Covid-19 in the age group above 18 years for restricted use in emergency situations.

Union Health Minister Mansukh Mandaviya tweeted the news.

In another tweet, he wrote, “This step will further strengthen our collective fight against the pandemic. India has harnessed its science, R&D, and human resources in the fight against Covid-19 under PM Narendra Modi’s leadership. With the science-driven approach & Sabka Prayas, we will defeat Covid-19.”